107 related articles for article (PubMed ID: 21220034)
1. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model.
Lee BH; Park Y; Kim JH; Kang KW; Lee SJ; Kim SJ; Kim BS
Sci Rep; 2020 Jul; 10(1):12641. PubMed ID: 32724129
[TBL] [Abstract][Full Text] [Related]
4. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
Shah GL; Landau H; Londono D; Devlin SM; Kosuri S; Lesokhin AM; Lendvai N; Hassoun H; Chung DJ; Koehne G; Jhanwar SC; Landgren O; Levine R; Giralt SA
Leuk Lymphoma; 2017 Aug; 58(8):1823-1831. PubMed ID: 28078910
[TBL] [Abstract][Full Text] [Related]
5. Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
D'Agostino M; Rota-Scalabrini D; Belotti A; Bertamini L; Arigoni M; De Sabbata G; Pietrantuono G; Pascarella A; Tosi P; Pisani F; Pescosta N; Ruggeri M; Rogers J; Olivero M; Garzia M; Galieni P; Annibali O; Monaco F; Liberati AM; Palmieri S; Stefanoni P; Zamagni E; Bruno B; Calogero RA; Boccadoro M; Musto P; Gay F
Blood Cancer J; 2024 Jun; 14(1):94. PubMed ID: 38849344
[TBL] [Abstract][Full Text] [Related]
6. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
[TBL] [Abstract][Full Text] [Related]
7. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.
D'Souza A; Pasquini M; Logan B; Giralt S; Krishnan A; Antin J; Howard A; Goodman S; Qazilbash M; Knust K; Sahebi F; Weisdorf D; Vesole D; Stadtmauer E; Maloney D; Hari P
Br J Haematol; 2017 Sep; 178(5):816-819. PubMed ID: 27292583
[No Abstract] [Full Text] [Related]
8. Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Lee L; Alrasheed N; Khandelwal G; Fitzsimons E; Richards H; Wilson W; Chavda SJ; Henry J; Conde L; De Massy MR; Chin M; Galas-Filipowicz D; Herrero J; Chain B; Quezada SA; Yong K
Front Immunol; 2021; 12():618610. PubMed ID: 33717112
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation.
Takahashi S; Minnie SA; Ensbey KS; Schmidt CR; Sekiguchi T; Legg SRW; Zhang P; Koyama M; Olver SD; Collinge AD; Keshmiri S; Comstock ML; Varelias A; Green DJ; Hill GR
Blood; 2024 Apr; 143(16):1656-1669. PubMed ID: 38295333
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.
Liu X; Wu F; Ye W; Deng J; Zhang M; Zhang C; Yu Q; Cao L; Gan S; Ma J
BMJ Open; 2024 Jan; 14(1):e071548. PubMed ID: 38216195
[TBL] [Abstract][Full Text] [Related]
11. Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021).
Shibayama H; Itagaki M; Handa H; Yokoyama A; Saito A; Kosugi S; Ota S; Yoshimitsu M; Tanaka Y; Kurahashi S; Fuchida SI; Iino M; Shimizu T; Moriuchi Y; Toyama K; Mitani K; Tsukune Y; Kada A; Tamura H; Abe M; Iwasaki H; Kuroda J; Takamatsu H; Sunami K; Kizaki M; Ishida T; Saito T; Matsumura I; Akashi K; Iida S
Int J Hematol; 2024 Jun; 119(6):707-721. PubMed ID: 38548963
[TBL] [Abstract][Full Text] [Related]
12. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
Chang H; Jiang N; Jiang H; Saha MN; Qi C; Xu W; Reece D
Haematologica; 2010 Sep; 95(9):1542-7. PubMed ID: 20421271
[TBL] [Abstract][Full Text] [Related]
13. Genomic Classification and Individualized Prognosis in Multiple Myeloma.
Maura F; Rajanna AR; Ziccheddu B; Poos AM; Derkach A; Maclachlan K; Durante M; Diamond B; Papadimitriou M; Davies F; Boyle EM; Walker B; Hultcrantz M; Silva A; Hampton O; Teer JK; Siegel EM; Bolli N; Jackson GH; Kaiser M; Pawlyn C; Cook G; Kazandjian D; Stein C; Chesi M; Bergsagel L; Mai EK; Goldschmidt H; Weisel KC; Fenk R; Raab MS; Van Rhee F; Usmani S; Shain KH; Weinhold N; Morgan G; Landgren O
J Clin Oncol; 2024 Apr; 42(11):1229-1240. PubMed ID: 38194610
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 1q21 abnormalities in multiple myeloma.
Schmidt TM; Fonseca R; Usmani SZ
Blood Cancer J; 2021 Apr; 11(4):83. PubMed ID: 33927196
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.
Cui J; Liu Y; Lv R; Yan W; Xu J; Li L; Du C; Yu T; Zhang S; Deng S; Sui W; Hao M; Yi S; Zou D; Qiu L; Xu Y; An G
Leukemia; 2024 Jun; 38(6):1299-1306. PubMed ID: 38609496
[TBL] [Abstract][Full Text] [Related]
16. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.
Rosean TR; Tompkins VS; Tricot G; Holman CJ; Olivier AK; Zhan F; Janz S
Immunol Res; 2014 Aug; 59(1-3):188-202. PubMed ID: 24845460
[TBL] [Abstract][Full Text] [Related]
17. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
Johnson TS; Sudha P; Liu E; Becker N; Robertson S; Blaney P; Morgan G; Chopra VS; Dos Santos C; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
Nat Commun; 2024 May; 15(1):4144. PubMed ID: 38755140
[TBL] [Abstract][Full Text] [Related]
18. SnapShot: Multiple Myeloma.
Braggio E; Kortüm KM; Stewart AK
Cancer Cell; 2015 Nov; 28(5):678-678.e1. PubMed ID: 26555176
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma: biology, standard therapy, and transplant therapy.
Gertz MA; Ghobrial I; Luc-Harousseau J
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):46-52. PubMed ID: 19147078
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities.
Zhou P; Li W; Zuo S; Ma R; Yuan X; Zhu Z
Leuk Lymphoma; 2023; 64(8):1373-1388. PubMed ID: 37300424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
